We are live on ! Find out more
DCM

DAFNA Capital Management Portfolio holdings

AUM $440M
1-Year Est. Return 109.12%
This Fund
S&P 500
This Quarter Est. Return
+9.27%
1 Year Est. Return
+109.12%
3 Year Est. Return
+239.59%
5 Year Est. Return
+227.89%
10 Year Est. Return
+3,611.91%
AUM
$423M
AUM Growth
+$4.74M
Cap. Flow
-$21.3M
Cap. Flow %
-5.03%
Top 10 Hldgs %
48.91%
Holding
89
New
6
Increased
19
Reduced
26
Closed
5

Top Buys

Rank Stock Value
1
LXEO icon
Lexeo Therapeutics
LXEO
+$2.99M
2
IDYA icon
IDEAYA Biosciences
IDYA
+$1.87M
3
BPMC
Blueprint Medicines
BPMC
+$1.69M
4
DAWN
Day One Biopharmaceuticals
DAWN
+$1.2M
5
ALLO icon
Allogene Therapeutics
ALLO
+$1.19M

Top Sells

Rank Stock Value
1
MORF
Morphic Holding, Inc. Common Stock
MORF
+$7.9M
2
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$4.27M
3
VKTX icon
Viking Therapeutics
VKTX
+$3.73M
4
SNDX icon
Syndax Pharmaceuticals
SNDX
+$2.69M
5
TSVT
2seventy bio
TSVT
+$1.9M

Sector Composition

Rank Sector Weight
1 Healthcare 86%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALEC icon
26
Alector
ALEC
$172M
$4.25M 1.01%
912,928
– –
RCUS icon
27
Arcus Biosciences
RCUS
$3.46B
$3.93M 0.93%
256,717
+3,500
+1% +$55.2K
LKFT
28
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.69B
$3.75M 0.89%
130,175
– –
PODD icon
29
Insulet
PODD
$9.45B
$3.7M 0.87%
15,900
– –
ALKS icon
30
Alkermes
ALKS
$8.14B
$3.38M 0.8%
120,700
– –
LRMR icon
31
Larimar Therapeutics
LRMR
$437M
$3.24M 0.76%
494,274
-145,700
-23% -$1.17M
CATX icon
32
Perspective Therapeutics
CATX
$338M
$3.07M 0.73%
230,322
-1,312
-0.6% -$17.4K
TSVT
33
DELISTED
2seventy bio
TSVT
$2.97M 0.7%
630,029
-420,680
-40% -$1.9M
SLRN
34
DELISTED
ACELYRIN
SLRN
$2.97M 0.7%
602,894
-90,715
-13% -$468K
ALLO icon
35
Allogene Therapeutics
ALLO
$670M
$2.94M 0.69%
1,050,118
+445,018
+74% +$1.19M
AQST icon
36
Aquestive Therapeutics
AQST
$479M
$2.94M 0.69%
589,561
+59,561
+11% +$232K
IPSC icon
37
Century Therapeutics
IPSC
$343M
$2.91M 0.69%
1,704,232
– –
ATXS
38
DELISTED
Astria Therapeutics
ATXS
$2.8M 0.66%
254,165
-20,000
-7% -$222K
BCYC
39
Bicycle Therapeutics
BCYC
$277M
$2.77M 0.65%
122,200
– –
STOK icon
40
Stoke Therapeutics
STOK
$2.05B
$2.55M 0.6%
207,427
– –
BWAY
41
Brainsway
BWAY
$634M
$2.32M 0.55%
502,692
-92,618
-16% -$341K
LXEO icon
42
Lexeo Therapeutics
LXEO
$364M
$2.27M 0.54%
+250,583
New +$2.99M
ARAY icon
43
Accuray
ARAY
$33.5M
$2.2M 0.52%
1,222,358
– –
SPRY icon
44
ARS Pharmaceuticals
SPRY
$548M
$2.15M 0.51%
148,294
-90,900
-38% -$1.08M
INGN icon
45
Inogen
INGN
$177M
$2.03M 0.48%
208,790
– –
CNTA
46
DELISTED
Centessa Pharmaceuticals
CNTA
$1.92M 0.45%
120,351
-2,531
-2% -$31K
MLYS icon
47
Mineralys Therapeutics
MLYS
$2.38B
$1.77M 0.42%
146,500
+27,500
+23% +$333K
AUTL
48
Autolus Therapeutics
AUTL
$511M
$1.77M 0.42%
486,667
+140,000
+40% +$558K
IMTX icon
49
Immatics
IMTX
$1.31B
$1.65M 0.39%
145,000
– –
ITOS
50
DELISTED
iTeos Therapeutics
ITOS
$1.65M 0.39%
161,584
+17,224
+12% +$263K
1
2
3 4

Similar funds

CDMG
Creek Drive Management Group San Francisco, California $439M AUM
SCP
SailingStone Capital Partners Houston, Texas $440M AUM 127.21% 1-Year Est. Return
CAAM
Cape Ann Asset Management London, United Kingdom $440M AUM 96.23% 1-Year Est. Return
HCM
Harvey Capital Management Palm Beach, Florida $439M AUM 37.68% 1-Year Est. Return
BOA
Birnam Oak Advisors New York $441M AUM 37.12% 1-Year Est. Return
ECA
Endeavour Capital Advisors Greenwich, Connecticut $441M AUM 21.38% 1-Year Est. Return
DBG
De Burlo Group Boston, Massachusetts $441M AUM 21.21% 1-Year Est. Return
SPT
Siemens Pension Trust Munich Germany, Germany $437M AUM 183.71% 1-Year Est. Return

DAFNA Capital Management's Q3 2024 Portfolio in Review

As of Q3 2024, DAFNA Capital Management held 89 positions worth $423M, up 1.1% from $419M the previous quarter. Its ten largest holdings account for 49% of the portfolio.

DAFNA Capital Management withdrew a net $21.3M in Q3 2024, closing 5 positions and reducing 26 holdings. Its most notable exit was Morphic Holding, Inc. Common Stock, an estimated $7.9M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, up from 86% a quarter earlier.

Against the trend, DAFNA Capital Management opened a new position in Lexeo Therapeutics worth $2.27M.

  • DAFNA Capital Management's largest Q3 2024 buy was Lexeo Therapeutics: 250,583 shares worth $2.27M.
  • DAFNA Capital Management added most to IDEAYA Biosciences in Q3 2024, an estimated $1.87M increase.
  • DAFNA Capital Management's biggest Q3 2024 reduction was State Street SPDR S&P Biotech ETF, cutting an estimated $4.27M.
  • DAFNA Capital Management fully exited Morphic Holding, Inc. Common Stock in Q3 2024, selling an estimated $7.9M.
  • DAFNA Capital Management's ten largest holdings make up 49% of its $423M portfolio in Q3 2024.
  • DAFNA Capital Management opened 6 new positions and closed 5 in Q3 2024.
  • DAFNA Capital Management's portfolio value rose 1.1% quarter-over-quarter to $423M.

Based on DAFNA Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.